<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: effectiveness", fill: "#a2add0"},
{source: "6: effectiveness", target: "6: products through clinical trials surgeons may", fill: "#a2add0"},
{source: "6: effectiveness", target: "8: addition surgeons may", fill: "#004f98"},
{source: "8: addition surgeons may", target: "8: liability risks", fill: "#004f98"},
{source: "8: liability risks", target: "8: new products", fill: "#004f98"},
{source: "8: new products", target: "8: uncertainty", fill: "#004f98"},
{source: "8: uncertainty", target: "8: reimbursement", fill: "#004f98"},
{source: "8: reimbursement", target: "8: from thirdparty payors", fill: "#004f98"},
{source: "8: addition surgeons may", target: "16: Technological ", fill: "#f400a1"},
{source: "16: Technological ", target: "16: advances could", fill: "#f400a1"},
{source: "16: advances could", target: "16: such treatments", fill: "#f400a1"},
{source: "16: such treatments", target: "16: effective", fill: "#f400a1"},
{source: "16: effective", target: "16: less expensive than using", fill: "#f400a1"},
{source: "16: less expensive than using", target: "16: products which could", fill: "#f400a1"},
{source: "16: Technological ", target: "22: Vinci Surgical System ", fill: "#faebd7"},
{source: "22: Vinci Surgical System ", target: "22: lengthy sales", fill: "#faebd7"},
{source: "22: lengthy sales", target: "22: major capital", fill: "#faebd7"},
{source: "22: major capital", target: "22: generally", fill: "#faebd7"},
{source: "22: generally", target: "22: senior management at purchasing institutions", fill: "#faebd7"},
{source: "22: Vinci Surgical System ", target: "31: challenges", fill: "#aa98a9"},
{source: "31: challenges", target: "31: local laws", fill: "#aa98a9"},
{source: "31: local laws", target: "31: protection against", fill: "#aa98a9"},
{source: "31: protection against", target: "31: infringement", fill: "#aa98a9"},
{source: "31: infringement", target: "31: intellectual property", fill: "#aa98a9"},
{source: "31: intellectual property", target: "31: protectionist laws", fill: "#aa98a9"},
{source: "31: protectionist laws", target: "31: favor local", fill: "#aa98a9"},
{source: "31: favor local", target: "31: competitors which could slow", fill: "#aa98a9"},
{source: "31: competitors which could slow", target: "31: international markets", fill: "#aa98a9"},
{source: "31: international markets", target: "31: establishing facilities", fill: "#aa98a9"},
{source: "31: establishing facilities", target: "31: operations", fill: "#aa98a9"},
{source: "31: operations", target: "31: organization capable", fill: "#aa98a9"},
{source: "31: organization capable", target: "31: supporting geographically", fill: "#aa98a9"},
{source: "31: supporting geographically", target: "31: dispersed operations", fill: "#aa98a9"},
{source: "31: challenges", target: "39: cannot assure", fill: "#f0e68c"},
{source: "39: cannot assure", target: "39: products will", fill: "#f0e68c"},
{source: "39: products will", target: "39: performance problems", fill: "#f0e68c"},
{source: "39: cannot assure", target: "51: may encounter", fill: "#f4c2c2"},
{source: "51: may encounter", target: "51: difficulties", fill: "#f4c2c2"},
{source: "51: difficulties", target: "51: scaling up production", fill: "#f4c2c2"},
{source: "51: scaling up production", target: "51: problems involving production yields", fill: "#f4c2c2"},
{source: "51: problems involving production yields", target: "51: quality control", fill: "#f4c2c2"},
{source: "51: quality control", target: "51: supply shortages", fill: "#f4c2c2"},
{source: "51: supply shortages", target: "51: qualified personnel", fill: "#f4c2c2"},
{source: "51: qualified personnel", target: "51: compliance with", fill: "#f4c2c2"},
{source: "51: compliance with", target: "51: foreign regulations", fill: "#f4c2c2"},
{source: "51: may encounter", target: "58: Furthermore ", fill: "#08457e"},
{source: "58: Furthermore ", target: "58: manufacturer", fill: "#08457e"},
{source: "58: manufacturer", target: "58: new manufacturer", fill: "#08457e"},
{source: "58: new manufacturer", target: "58: facilities", fill: "#08457e"},
{source: "58: facilities", target: "58: comply with quality standards", fill: "#08457e"},
{source: "58: comply with quality standards", target: "58: regulations", fill: "#08457e"},
{source: "58: regulations", target: "58: guidelines", fill: "#08457e"},
{source: "58: Furthermore ", target: "74: requirement", fill: "#ffa089"},
{source: "74: requirement", target: "74: effective", fill: "#ffa089"},
{source: "74: effective", target: "74: public companies", fill: "#ffa089"},
{source: "74: public companies", target: "74: annual periods beginning", fill: "#ffa089"},
{source: "74: requirement", target: "90: requirements", fill: "#826644"},
{source: "90: requirements", target: "90: necessary clearances", fill: "#826644"},
{source: "90: requirements", target: "149: commercial success will depend", fill: "#ff8243"},
{source: "149: commercial success will depend", target: "149: intellectual", fill: "#ff8243"},
{source: "149: intellectual", target: "149: technologies contained", fill: "#ff8243"},
{source: "149: technologies contained", target: "149: on successfully defending", fill: "#ff8243"},
{source: "149: on successfully defending", target: "149: property against third party challenges", fill: "#ff8243"},
{source: "149: commercial success will depend", target: "START_HERE", fill: "#ff8243"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>IT Consulting and Other Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Formally complain</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effectiveness">Effectiveness</a></td>
      <td>Effectiveness is the capability of producing a desired result or the ability to produce desired output. When something is deemed effective, it means it has an intended or expected outcome, or produces a deep, vivid impression.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_altruism">Effective altruism</a></td>
      <td>Effective altruism (EA) is a philosophical and social movement that advocates "using evidence and reason to figure out how to benefit others as much as possible, and taking action on that basis". People who pursue the goals of effective altruism are labeled effective altruists.Common practices of effective altruists include significant charitable donation, and choosing careers based on the amount of good that the career achieves, which may include the strategy of earning to give.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_temperature">Effective temperature</a></td>
      <td>The effective temperature of a body such as a star or planet is the temperature of a black body that would emit the same total amount of electromagnetic radiation.  Effective temperature is often used as an estimate of a body's surface temperature when the body's emissivity curve (as a function of wavelength) is not known.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_7_Habits_of_Highly_Effective_People">The 7 Habits of Highly Effective People</a></td>
      <td>The 7 Habits of Highly Effective People, first published in 1989, is a business and self-help book written by Stephen R. Covey. Covey presents an approach to being effective in attaining goals by aligning oneself to what he calls "true north" principles based on a character ethic that he presents as universal and timeless.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_demand">Effective demand</a></td>
      <td>In economics, effective demand (ED) in a market is the demand for a product or service which occurs when purchasers are constrained in a different market.  It contrasts with notional demand, which is the demand that occurs when purchasers are not constrained in any other market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_radiated_power">Effective radiated power</a></td>
      <td>Effective radiated power (ERP), synonymous with equivalent radiated power,  is an IEEE standardized definition of directional radio frequency (RF) power, such as that emitted by a radio transmitter.  It is the total power in watts that would have to be radiated by a half-wave dipole antenna to give the same radiation intensity (signal strength or power flux density in watts per square meter) as the actual source antenna at a distant receiver located in the direction of the antenna's strongest beam (main lobe).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_date">Effective date</a></td>
      <td>An effective date or as of date is the date upon which something is considered to take effect, which may be a past, present or future date.  This may be different from the date upon which the event occurs or is recorded.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_potential">Effective potential</a></td>
      <td>The effective potential (also known as effective potential energy) combines multiple, perhaps opposing, effects into a single potential. In its basic form, it is the sum of the 'opposing' centrifugal potential energy with the potential energy of a dynamical system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ZEUS_robotic_surgical_system">ZEUS robotic surgical system</a></td>
      <td>The ZEUS Robotic Surgical System (ZRSS) was a medical robot designed to assist in surgery, originally produced by the American robotics company Computer Motion. Its predecessor, AESOP, was cleared by the Food and Drug Administration in 1994 to assist surgeons in minimally invasive surgery.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hardware_random_number_generator">Hardware random number generator</a></td>
      <td>In computing, a hardware random number generator (HRNG) or true random number generator (TRNG) is a device that generates random numbers from a physical process, rather than by means of an algorithm.  Such devices are often based on microscopic phenomena that generate low-level, statistically random "noise" signals, such as thermal noise, the photoelectric effect, involving a beam splitter, and other quantum phenomena.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Synchroscope">Synchroscope</a></td>
      <td>In AC electrical power systems, a synchroscope is a device that indicates the degree to which two systems (generators or power networks) are synchronized with each other.For two electrical systems to be synchronized, both systems must operate at the same frequency, and the phase angle between the systems must be zero (and two polyphase systems must have the same phase sequence). Synchroscopes measure and display the frequency difference and phase angle between two power systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-functional_requirement">Non-functional requirement</a></td>
      <td>In systems engineering and requirements engineering, a non-functional requirement (NFR) is a requirement that specifies criteria that can be used to judge the operation of a system, rather than specific behaviours. They are contrasted with functional requirements that define specific behavior or functions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_United_States_citizens">Visa requirements for United States citizens</a></td>
      <td>As of 25 February 2022, Holders of a United States passport could travel to 186 countries and territories without a travel visa, or with a visa on arrival. The United States passport currently ranks 6th in terms of travel freedom (tied with the passports of Czech Republic, Greece, Malta, Norway, and the UK) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_elicitation">Requirements elicitation</a></td>
      <td>In requirements engineering, requirements elicitation is the practice of researching and discovering the requirements of a system from users, customers, and other stakeholders. The practice is also sometimes referred to as "requirement gathering".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_requirements_document">Market requirements document</a></td>
      <td>A market requirements document (MRD) in project management and systems engineering, is a document that expresses the customer's wants and needs for the product or service.\nIt is typically written as a part of product marketing or product management.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_requirements">Business requirements</a></td>
      <td>Business requirements, also known as stakeholder requirements specifications (StRS), describe the characteristics of a proposed system from the viewpoint of the system's end user like a CONOPS. Products, systems, software, and processes are ways of how to deliver, satisfy, or meet business requirements.  Consequently, business requirements are often discussed in the context of developing or procuring software or other systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_disability">Intellectual disability</a></td>
      <td>Intellectual disability (ID), also known as general learning disability in the United Kingdom and formerly mental retardation (MR), is a generalized neurodevelopmental disorder characterized by significantly impaired intellectual and adaptive functioning. It is defined by an IQ under 70, in addition to deficits in two or more adaptive behaviors that affect everyday, general living.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectualism">Intellectualism</a></td>
      <td>Intellectualism is the mental perspective that emphasizes the use, the development, and the exercise of the intellect; and also identifies the life of the mind of the intellectual person. In the field of philosophy, "intellectualism" is synonymous with rationalism, knowledge derived from reason.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_honesty">Intellectual honesty</a></td>
      <td>Intellectual honesty is an applied method of problem solving, characterised by an unbiased, honest attitude, which can be demonstrated in a number of different ways:\n\nOne's personal beliefs or politics do not interfere with the pursuit of truth;\nRelevant facts and information are not purposefully omitted even when such things may contradict one's hypothesis;\nFacts are presented in an unbiased manner, and not twisted to give misleading impressions or to support one view over another;\nReferences, or earlier work, are acknowledged where possible, and plagiarism is avoided.Harvard ethicist Louis M. Guenin describes the "kernel" of intellectual honesty to be "a virtuous disposition to eschew deception when given an incentive for deception".Intentionally committed fallacies in debates and reasoning are called intellectual dishonesty.\n\n\n== See also ==\nAcademic honesty\nConflict of interest\nEpistemic feedback\nGood faith\nIntellectual\nList of fallacies\nScientific method\nSophism\nSystemic bias\n\n\n== References ==\nNotes\n\nFurther reading\n\nToledo-Pereyra, Luis H. (2002).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_virtue">Intellectual virtue</a></td>
      <td>Intellectual virtues are qualities of mind and character that promote intellectual flourishing, critical thinking, and the pursuit of truth. They include: intellectual responsibility, perseverance, open-mindedness, empathy, integrity, intellectual courage, confidence in reason, love of truth, intellectual humility, imaginativeness, curiosity, fair-mindedness, and autonomy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_functioning">Intellectual functioning</a></td>
      <td>Intellectual functioning refers to the "general mental ability that includes reasoning, planning, problem solving, abstract thinking, comprehending complex ideas, learning quickly and learning from experience". Significantly limited or impaired intellectual functioning characterizes intellectual disabilities.Ageing has been shown to cause a decline in intellectual functioning.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_giftedness">Intellectual giftedness</a></td>
      <td>Intellectual giftedness is an intellectual ability significantly higher than average. It is a characteristic of children, variously defined, that motivates differences in school programming.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>INTUITIVE SURGICAL INC      ITEM 1A RISK FACTORS          RISKS RELATING TO OUR BUSINESS          IF OUR PRODUCTS DO NOT ACHIEVE MARKET ACCEPTANCE, WE WILL NOT BE ABLE TO     GENERATE THE REVENUE NECESSARY TO SUPPORT OUR BUSINESS          The  da  Vinci  Surgical  System  and  our  other products represent a     <font color="blue">fundamentally</font> new way of performing surgery</td>
    </tr>
    <tr>
      <td><font color="blue">Achieving </font>physician, patient     and third-party payor <font color="blue">acceptance</font> of da Vinci <font color="blue">surgery as</font> a <font color="blue">preferred method</font>     of performing <font color="blue">surgery will</font> be crucial to our success</td>
    </tr>
    <tr>
      <td>If our products fail     to achieve market <font color="blue">acceptance</font>, hospitals will not purchase our products and     we  will  not be able to generate the <font color="blue">revenue necessary</font> to support our     business</td>
    </tr>
    <tr>
      <td>We believe that physicians’ and third-party payors’ <font color="blue">acceptance</font> of     the benefits of procedures performed using our <font color="blue">products will</font> be essential     for <font color="blue">acceptance</font> of our <font color="blue">products by patients</font></td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>will not recommend     the use of our <font color="blue">products unless</font> we can <font color="blue">demonstrate</font> that they produce results     comparable or superior to <font color="blue">existing surgical techniques</font></td>
    </tr>
    <tr>
      <td>Even if we can prove     the <font color="blue"><font color="blue">effective</font>ness</font> of our products through <font color="blue">clinical trials</font>, surgeons may     elect not to use our products for any number of other reasons</td>
    </tr>
    <tr>
      <td>For example,     <font color="blue">cardiologists may continue</font> to <font color="blue">recommend conventional heart surgery simply</font>     because <font color="blue">such surgery</font> is <font color="blue">already widely accepted</font></td>
    </tr>
    <tr>
      <td>In addition, surgeons may     be slow to adopt our products because of the perceived <font color="blue"><font color="blue">liability</font> risks</font>     arising from the use of <font color="blue">new products</font> and the <font color="blue">uncertainty</font> of <font color="blue">reimbursement</font>     from third-party payors</td>
    </tr>
    <tr>
      <td>We expect that there will be a <font color="blue">learning process involved</font> for <font color="blue">surgical teams</font>     to <font color="blue">become proficient</font> in the use of our products</td>
    </tr>
    <tr>
      <td>Broad use of our products     will require training of <font color="blue">surgical teams</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> could be delayed     by  the time required to complete this training</td>
    </tr>
    <tr>
      <td>We may not be able to     rapidly train <font color="blue">surgical teams</font> in <font color="blue">numbers sufficient</font> to <font color="blue">generate adequate</font>     demand for our products</td>
    </tr>
    <tr>
      <td>BECAUSE OUR MARKETS ARE HIGHLY COMPETITIVE, CUSTOMERS MAY CHOOSE TO PURCHASE     OUR COMPETITORS’ PRODUCTS OR MAY NOT ACCEPT DA VINCI SURGERY, WHICH WOULD     RESULT IN REDUCED REVENUE AND LOSS OF MARKET SHARE          Da Vinci surgery is a <font color="blue">new <font color="blue">technology</font></font> that <font color="blue">will compete with established</font> and     <font color="blue">emerging treatment options</font> in <font color="blue">both disease <font color="blue">management</font></font> and <font color="blue">reconstructive</font>     <font color="blue">medical procedures</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">competitive</font> treatment options may</font> take the form of     traditional  minimally  invasive surgery, open surgery, interventional     approaches, or <font color="blue">pharmacological regimens</font></td>
    </tr>
    <tr>
      <td>Some of these procedures are widely     accepted in the <font color="blue">medical community</font> and in many cases have a <font color="blue">long history</font> of     use</td>
    </tr>
    <tr>
      <td><font color="blue">Technological </font><font color="blue">advances could</font> make <font color="blue">such treatments</font> more <font color="blue">effective</font> or     <font color="blue"><font color="blue">less expensive than</font> using</font> our products, which could render our products     obsolete or unmarketable</td>
    </tr>
    <tr>
      <td>We cannot be certain that <font color="blue">physicians will use</font> our     products  to  replace or <font color="blue">supplement established treatments</font> or that our     <font color="blue">products will</font> be <font color="blue"><font color="blue">competitive</font> with current</font> or <font color="blue">future <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">may face <font color="blue">competition</font> from companies</font> that develop wristed,     robotic or computer-assisted surgical systems and products in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">revenues may</font> be reduced or eliminated if our <font color="blue">competitors</font> develop and     <font color="blue">market products</font> that are more <font color="blue">effective</font> or <font color="blue">less expensive than</font> our products</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">compete successfully</font>, our <font color="blue"><font color="blue">revenues will</font> suffer</font></td>
    </tr>
    <tr>
      <td>We may     not be able to maintain or improve our <font color="blue"><font color="blue">competitive</font> position against current</font>     or potential <font color="blue">competitors</font>, especially those <font color="blue">with greater resources</font></td>
    </tr>
    <tr>
      <td>WE EXPERIENCE LONG AND VARIABLE SALES CYCLES, WHICH COULD HAVE A NEGATIVE     IMPACT ON OUR RESULTS OF OPERATIONS FOR ANY GIVEN QUARTER          Our da <font color="blue">Vinci Surgical System </font>has a <font color="blue">lengthy sales</font> and purchase order cycle     because it is a <font color="blue">major capital</font> item and <font color="blue">generally</font> requires the approval of     <font color="blue">senior <font color="blue">management</font> at purchasing institutions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors may contribute</font>     to substantial <font color="blue">fluctuations</font> in our quarterly operating results</td>
    </tr>
    <tr>
      <td>Because of     these <font color="blue">fluctuations</font>, it is likely that in some future quarters our operating     results  will  fall  below  the <font color="blue">expectations</font> of securities analysts or     investors</td>
    </tr>
    <tr>
      <td>If that happens, the <font color="blue">market price</font> of our <font color="blue">stock <font color="blue">would likely</font></font>     decrease</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations</font> also mean that you will not be able to rely     upon our operating results in any <font color="blue">particular period as</font> an <font color="blue">indication</font> of     <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">introduction</font> of <font color="blue">new products</font> could     <font color="blue">adversely impact</font> our sales cycle, as customers take <font color="blue">additional</font> time to     assess the benefits and costs of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>INTERNATIONAL SALES OF OUR PRODUCTS ACCOUNT FOR A SIGNIFICANT PORTION OF OUR     REVENUES, WHICH EXPOSES US TO RISKS INHERENT IN INTERNATIONAL OPERATIONS     OUR  GROWTH MAY BE LIMITED IF WE ARE UNABLE TO SUCCESSFULLY MANAGE OUR     INTERNATIONAL ACTIVITIES          Our business <font color="blue">currently depends</font> in part on our <font color="blue">activities</font> in Europe and other     <font color="blue">foreign markets</font></td>
    </tr>
    <tr>
      <td>Sales to markets outside of the <font color="blue"><font color="blue">United States</font> </font>accounted for     <font color="blue">approximately</font>  17prca, 21prca, and 24prca of our sales for 2005, 2004 and 2003,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We are subject to a number of <font color="blue">challenges</font> that <font color="blue">specifically</font>     relate to our <font color="blue">international</font> business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">challenges</font> include:           •   failure of <font color="blue">local laws</font> to provide the same degree of <font color="blue">protection against</font>     <font color="blue">infringement</font> of our <font color="blue"><font color="blue">intellectual</font> property</font>;           •   <font color="blue">protectionist laws</font> and business practices that <font color="blue">favor local</font>     <font color="blue">competitors</font>, which could slow our growth in <font color="blue">international</font> markets;           •   the risks associated with foreign currency exchange rate fluctuation;           •   the expense of <font color="blue">establishing <font color="blue">facilities</font></font> and <font color="blue">operations</font> in new foreign     markets; and           •   building an <font color="blue">organization capable</font> of <font color="blue">supporting geographically</font>     dispersed <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Currently, more than half of our <font color="blue">international</font> sales are <font color="blue">denominated</font> in     <font color="blue"><font color="blue">United States</font> </font>dollars</td>
    </tr>
    <tr>
      <td>As a result, an increase in the value of the United     States <font color="blue">dollar relative</font> to <font color="blue">foreign currencies could</font> make our <font color="blue">products less</font>     <font color="blue">competitive</font> in <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>If we are unable to meet and overcome     these <font color="blue">challenges</font>, our <font color="blue">international</font> <font color="blue">operations</font> may not be successful, which     <font color="blue">would limit</font> the growth of our business</td>
    </tr>
    <tr>
      <td>IF  DEFECTS  ARE  DISCOVERED  IN OUR PRODUCTS, WE MAY INCUR ADDITIONAL     UNFORESEEN COSTS, HOSPITALS MAY NOT PURCHASE OUR PRODUCTS AND OUR REPUTATION     MAY SUFFER          Our products incorporate mechanical parts, electrical <font color="blue">components</font>, optical     <font color="blue">components</font>  and  <font color="blue">computer software</font>, any of which can <font color="blue">contain errors</font> or     failures, especially when <font color="blue">first introduced</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">new products</font> or     <font color="blue">enhancements may contain undetected errors</font> or <font color="blue">performance problems</font> that,     <font color="blue">despite testing</font>, are <font color="blue">discovered only</font> after <font color="blue">commercial shipment</font></td>
    </tr>
    <tr>
      <td>Because our     products are designed to be used to perform <font color="blue">complex <font color="blue">surgical procedures</font></font>, we     expect  that  our <font color="blue">customers will</font> have an <font color="blue">increased sensitivity</font> to such     defects</td>
    </tr>
    <tr>
      <td>In the past, we have <font color="blue">voluntarily</font> recalled certain <font color="blue">products as</font> a     result of <font color="blue">performance problems</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our <font color="blue">products will</font>     not  experience  errors  or  <font color="blue">performance problems</font> in the future</td>
    </tr>
    <tr>
      <td>If we     experience flaws or <font color="blue">performance problems</font>, any of the <font color="blue">following could</font> occur:           •   delays in <font color="blue">product shipments</font>;           •   loss of revenue;           •   delay in market <font color="blue">acceptance</font>;           •   diversion of our resources;           •   damage to our reputation;           •   <font color="blue">product recalls</font>;           •   <font color="blue">increased service</font> or <font color="blue">warranty costs</font>; or           •   <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>THE USE OF OUR PRODUCTS COULD RESULT IN PRODUCT LIABILITY CLAIMS THAT COULD     BE EXPENSIVE, DIVERT MANAGEMENT’S ATTENTION AND HARM OUR BUSINESS          Our business <font color="blue">exposes us</font> to <font color="blue"><font color="blue">significant</font> risks</font> of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>The medical device industry has <font color="blue"><font color="blue">historically been</font> litigious</font>, and we face     <font color="blue">financial exposure</font> to <font color="blue">product <font color="blue">liability</font></font> claims if the use of our products                                           21     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font>were to cause injury or death</td>
    </tr>
    <tr>
      <td>There is also the <font color="blue">possibility</font> that defects in     the  design or <font color="blue">manufacture</font> of our products might necessitate a product     recall</td>
    </tr>
    <tr>
      <td>Any <font color="blue">weaknesses</font> in training and <font color="blue">services associated with</font> our products     may also be subject to <font color="blue">product <font color="blue">liability</font></font> lawsuits</td>
    </tr>
    <tr>
      <td>Although we maintain     <font color="blue">product <font color="blue">liability</font></font> insurance, the <font color="blue">coverage limits</font> of these <font color="blue">policies may</font> not     be adequate to <font color="blue">cover future</font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">Particularly </font>as sales of our products     increase, we may be unable to maintain <font color="blue">product <font color="blue">liability</font></font> insurance in the     future at satisfactory rates or in <font color="blue">adequate amounts</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">product <font color="blue">liability</font></font>     claim,  <font color="blue">regardless</font>  of  its merit or eventual outcome, could result in     <font color="blue"><font color="blue">significant</font> legal defense costs</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims have been made     against our company in the past</td>
    </tr>
    <tr>
      <td>A <font color="blue">product <font color="blue">liability</font></font> claim or any product     <font color="blue">recalls could also harm</font> our reputation or result in a decline in revenues</td>
    </tr>
    <tr>
      <td>WE MAY ENCOUNTER MANUFACTURING PROBLEMS OR DELAYS THAT COULD RESULT IN LOST     REVENUE          Manufacturing  our  products  is  a  <font color="blue">complex process</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter</font>     <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">scaling up production</font> of our products, including:           •   <font color="blue">problems involving production yields</font>;           •   <font color="blue">quality control</font> and assurance;           •   component <font color="blue">supply shortages</font>;           •   shortages of <font color="blue">qualified personnel</font>; and           •   <font color="blue">compliance with</font> state, federal and <font color="blue">foreign <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>If demand for our <font color="blue">products exceeds</font> our <font color="blue"><font color="blue">manufacturing</font> capacity</font>, we could     develop  a substantial backlog of <font color="blue">customer orders</font></td>
    </tr>
    <tr>
      <td>If we are unable to     maintain larger-scale <font color="blue">manufacturing</font> capabilities, our ability to generate     <font color="blue">revenues will</font> be limited and our reputation in the <font color="blue">marketplace could</font> be     damaged</td>
    </tr>
    <tr>
      <td>OUR RELIANCE ON SOLE AND SINGLE SOURCE SUPPLIERS COULD HARM OUR ABILITY TO     MEET DEMAND FOR OUR PRODUCTS IN A TIMELY MANNER OR WITHIN BUDGET          Some  of the <font color="blue">components</font> necessary for the assembly of our products are     currently  provided  to us by sole-sourced suppliers or single-sourced     suppliers</td>
    </tr>
    <tr>
      <td>We purchase <font color="blue">components</font> through purchase orders rather than     long-term supply <font color="blue">agreements</font> and <font color="blue">generally</font> do not maintain large volumes of     inventory</td>
    </tr>
    <tr>
      <td>The <font color="blue">disruption</font> or <font color="blue">termination</font> of the supply of <font color="blue">components</font> could     cause a <font color="blue"><font color="blue">significant</font> increase</font> in the costs of these <font color="blue">components</font>, which could     affect our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">disruption</font> or <font color="blue">termination</font> in the supply of     <font color="blue">components</font>  could  also result in our <font color="blue">inability</font> to meet demand for our     products,  which  <font color="blue">could harm</font> our ability to generate revenues, lead to     <font color="blue">customer dissatisfaction</font> and damage our reputation</td>
    </tr>
    <tr>
      <td>Furthermore, if we are     required to change the <font color="blue">manufacture</font>r of a key component of our products, we     may be required to verify that the new <font color="blue">manufacture</font>r maintains <font color="blue">facilities</font> and     procedures  that <font color="blue"><font color="blue">comply with</font> <font color="blue">quality standards</font></font> and with all applicable     <font color="blue">regulations</font> and <font color="blue">guidelines</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">delays associated with</font> the <font color="blue">verification</font> of a     new <font color="blue">manufacture</font>r could delay our ability to <font color="blue">manufacture</font> our products in a     <font color="blue">timely manner</font> or <font color="blue">within budget</font></td>
    </tr>
    <tr>
      <td>IF  INSTITUTIONS  OR  SURGEONS ARE UNABLE TO OBTAIN REIMBURSEMENT FROM     THIRD-PARTY PAYORS FOR PROCEDURES USING OUR PRODUCTS, OR IF REIMBURSEMENT IS     INSUFFICIENT TO COVER THE COSTS OF PURCHASING OUR PRODUCTS, WE MAY BE UNABLE     TO GENERATE SUFFICIENT SALES TO SUPPORT OUR BUSINESS          Domestic <font color="blue">institutions will typically bill</font> the services performed with our     products to various third-party payors, such as Medicare, Medicaid and other     <font color="blue"><font color="blue">government</font> programs</font> and <font color="blue">private insurance</font> plans</td>
    </tr>
    <tr>
      <td>If hospitals do not obtain     sufficient <font color="blue">reimbursement</font> from third-party payors for procedures performed     with our products, or if <font color="blue">government</font> and private payors’ policies do not     permit <font color="blue">reimbursement</font> for <font color="blue">surgical procedures</font> performed using our products,     we  may  not be able to generate the <font color="blue">revenues necessary</font> to support our     business</td>
    </tr>
    <tr>
      <td>Our  success in <font color="blue">international</font> markets also depends upon the     <font color="blue">eligibility</font> of our products for <font color="blue">reimbursement</font> through <font color="blue">government</font>- sponsored     <font color="blue">health care payment</font>                                           22     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>systems and third-party payors</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font><font color="blue">practices vary <font color="blue">significant</font>ly</font>     <font color="blue">by country</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">international</font> markets have <font color="blue">government</font>-managed healthcare     systems that control <font color="blue">reimbursement</font> for <font color="blue">new products</font> and procedures</td>
    </tr>
    <tr>
      <td><font color="blue">Other     </font><font color="blue">foreign markets</font> have both <font color="blue">private insurance</font> systems and <font color="blue">government</font>-managed     systems that control <font color="blue">reimbursement</font> for <font color="blue">new products</font> and procedures</td>
    </tr>
    <tr>
      <td><font color="blue">Market     </font><font color="blue">acceptance</font> of our <font color="blue">products may depend on</font> the <font color="blue">availability</font> and level of     <font color="blue">reimbursement</font> in any <font color="blue">country within</font> a particular time</td>
    </tr>
    <tr>
      <td>In addition, health     <font color="blue">care cost containment efforts</font> similar to those we face in the <font color="blue"><font color="blue">United States</font> </font>    are prevalent in many of the other countries in which we intend to sell our     products and these efforts are expected to continue</td>
    </tr>
    <tr>
      <td>IF WE LOSE OUR KEY PERSONNEL OR ARE UNABLE TO ATTRACT AND RETAIN ADDITIONAL     PERSONNEL, OUR ABILITY TO COMPETE WILL BE HARMED          We are <font color="blue">highly dependent on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font> and     <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">development</font></font> plans depend, in part, on our     ability  to attract and retain <font color="blue">engineers with</font> experience in mechanics,     software and optics</td>
    </tr>
    <tr>
      <td><font color="blue">Attracting </font>and retaining <font color="blue">qualified personnel</font> will be     critical to our success, and <font color="blue">competition</font> for <font color="blue">qualified personnel</font> is intense</td>
    </tr>
    <tr>
      <td>We may not be able to attract and retain <font color="blue">personnel on</font> acceptable <font color="blue">terms given</font>     the <font color="blue">competition</font> for <font color="blue">such personnel among <font color="blue">technology</font></font> and <font color="blue">healthcare companies</font>     and <font color="blue">universities</font></td>
    </tr>
    <tr>
      <td>The loss of any of these persons or our <font color="blue">inability</font> to     attract and retain <font color="blue">qualified personnel</font> <font color="blue">could harm</font> our business and our     ability to compete</td>
    </tr>
    <tr>
      <td>RECENT CHANGES IN THE REQUIRED ACCOUNTING TREATMENT FOR STOCK OPTIONS WILL     HAVE A MATERIAL ADVERSE IMPACT ON OUR NET INCOME AND NET INCOME PER SHARE     AND MAY ADVERSELY AFFECT OUR STOCK PRICE          <font color="blue">In <font color="blue">December </font></font>2004, the <font color="blue">Financial Accounting Standards Board </font>issued SFAS     Nodtta 123 (revised 2004) “Share Based Payment,” or SFAS 123R, pursuant to     which we must measure all stock-based <font color="blue">compensation</font> awards, including grants     of employee <font color="blue">stock options</font>, using a <font color="blue">fair value</font>-based method and <font color="blue">record such</font>     expense  in our <font color="blue"><font color="blue">consolidated financial</font> statements</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">requirement</font> to     expense stock-based <font color="blue">compensation</font> awards is <font color="blue">effective</font> for <font color="blue">public companies</font>     for <font color="blue">annual periods beginning</font> after June 15, 2005</td>
    </tr>
    <tr>
      <td>Accordingly, SFAS 123R     will be <font color="blue">effective</font> for us starting January 1, 2006</td>
    </tr>
    <tr>
      <td>Our net income and our     <font color="blue">earnings per</font> share will be <font color="blue"><font color="blue">significant</font>ly reduced</font> or may reflect a loss</td>
    </tr>
    <tr>
      <td>We     currently calculate stock-based <font color="blue">compensation</font> expense using the Black-Scholes     option-pricing model and disclose the pro forma impact on net income (loss)     and net income (loss) per share in our <font color="blue"><font color="blue">consolidated financial</font> statements</font></td>
    </tr>
    <tr>
      <td>A     fair  <font color="blue">value based model such as</font> the Black-Scholes option-pricing model     requires the input of <font color="blue"><font color="blue">highly subjective</font> <font color="blue">assumptions</font></font> and does not <font color="blue">necessarily</font>     provide  a <font color="blue">reliable single</font> measure of the <font color="blue">fair value</font> of <font color="blue">stock options</font></td>
    </tr>
    <tr>
      <td><font color="blue">Assumptions </font>used under the Black-Scholes option-pricing model that are     <font color="blue">highly subjective</font> include the expected <font color="blue">stock price <font color="blue">volatility</font></font> and expected     life of an option</td>
    </tr>
    <tr>
      <td>The <font color="blue">actual impact on</font> our results of <font color="blue">operations</font> upon     adoption of the new standard could be <font color="blue"><font color="blue">significant</font>ly different from</font> the pro     forma  information  included  in  Note 2 to our <font color="blue">consolidated financial</font>     statements  due to <font color="blue">variations</font> in estimates and <font color="blue"><font color="blue">assumptions</font> used</font> in the     <font color="blue">calculation</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">assumptions</font> will</font> require <font color="blue">management</font> to predict the future     <font color="blue">stock performance</font> and employees’ stock option exercise behavior, which are     beyond <font color="blue">management</font>’s control</td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>will apply our <font color="blue">best judgement</font> in     making the <font color="blue">assumptions</font></td>
    </tr>
    <tr>
      <td>However, the actual stock based <font color="blue">compensation</font> expense     upon adoption of the new standard could be <font color="blue"><font color="blue">significant</font>ly different from</font> the     pro forma information</td>
    </tr>
    <tr>
      <td>RISKS RELATING TO OUR REGULATORY ENVIRONMENT          OUR PRODUCTS ARE SUBJECT TO A LENGTHY AND UNCERTAIN DOMESTIC REGULATORY     PROCESS IF WE DO NOT OBTAIN AND MAINTAIN THE NECESSARY DOMESTIC REGULATORY     APPROVALS, WE WILL NOT BE ABLE TO MARKET AND SELL OUR PRODUCTS IN THE UNITED     STATES          Our products and <font color="blue">operations</font> are subject to extensive regulation in the     <font color="blue"><font color="blue">United States</font> </font>by the US Food and Drug Administration, or FDA The FDA     regulates the research, testing, <font color="blue">manufacturing</font>, safety, labeling, storage,     record keeping, promotion, distribution and production of <font color="blue">medical devices</font> in     the <font color="blue"><font color="blue">United States</font> </font>to ensure that                                           23     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">medical products</font> distributed domestically</font> are safe and <font color="blue">effective</font> for their     <font color="blue"><font color="blue">intended use</font>s</font></td>
    </tr>
    <tr>
      <td>In order for us to <font color="blue">market certain products</font> for use in the     United  States,  we <font color="blue">generally</font> must first obtain <font color="blue">clearance from</font> the FDA     pursuant to Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or     <font color="blue">FFDCA Clearance </font>under Section 510(k) requires <font color="blue">demonstration</font> that a new     device is <font color="blue"><font color="blue">substantially</font> equivalent</font> to another device with 510(k) clearance     or <font color="blue">grandfather status</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue"><font color="blue">significant</font>ly modify</font> our products after they     receive FDA clearance, the FDA may require us to submit a separate 510(k) or     <font color="blue">premarket approval <font color="blue">application</font></font>, or PMA, for the <font color="blue">modified product</font> before we     are permitted to market the products in the US In addition, if we develop     products  in  the  future  that are not considered to be <font color="blue">substantially</font>     equivalent to a device with 510(k) clearance or <font color="blue">grandfather status</font>, we will     be required to obtain FDA <font color="blue">approval by submitting</font> a PMA         The FDA may not act favorably or quickly in its review of our 510(k) or PMA     <font color="blue">submissions</font>, or we <font color="blue">may encounter</font> <font color="blue">significant</font> <font color="blue"><font color="blue">difficult</font>ies</font> and costs in our     efforts to obtain FDA clearance or approval, all of <font color="blue">which could delay</font> or     <font color="blue">preclude sale</font> of <font color="blue">new products</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Furthermore, the FDA may     request <font color="blue">additional</font> data or require us to <font color="blue">conduct further testing</font>, or compile     more data, including <font color="blue">clinical data</font> and <font color="blue">clinical studies</font>, in support of a     510(k)  submission</td>
    </tr>
    <tr>
      <td>The  FDA  may also, instead of <font color="blue">accepting</font> a 510(k)     submission, require us to submit a PMA, which is typically a much more     complex and <font color="blue">burdensome <font color="blue">application</font> than</font> a 510(k)</td>
    </tr>
    <tr>
      <td>To support a PMA, the FDA     would  likely  require that we <font color="blue">conduct one</font> or more <font color="blue">clinical studies</font> to     <font color="blue">demonstrate</font> that the device is safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>We may not be able to     meet the <font color="blue">requirement</font>s to obtain 510(k) clearance or PMA approval, or the FDA     may not grant any <font color="blue">necessary <font color="blue">clearances</font></font> or approvals</td>
    </tr>
    <tr>
      <td>In addition, the FDA     may place <font color="blue"><font color="blue">significant</font> limitations upon</font> the <font color="blue">intended use</font> of our <font color="blue">products as</font> a     condition to a 510(k) clearance or PMA approval</td>
    </tr>
    <tr>
      <td>Product <font color="blue"><font color="blue">application</font>s</font> can     also  be  denied or <font color="blue">withdrawn due</font> to failure to <font color="blue"><font color="blue">comply with</font> <font color="blue">regulatory</font></font>     <font color="blue">requirement</font>s or the occurrence of <font color="blue">unforeseen problems following clearance</font> or     approval</td>
    </tr>
    <tr>
      <td>Any delays or failure to obtain FDA clearance or approvals of new     products we develop, any <font color="blue">limitations imposed by</font> the FDA <font color="blue">on new product use</font>,     or the costs of obtaining FDA clearance or <font color="blue">approvals could</font> have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In order to conduct a <font color="blue">clinical investigation involving human subjects</font> for     the purpose of <font color="blue">demonstrating</font> the safety and <font color="blue"><font color="blue">effective</font>ness</font> of a device, a     company must, among other things, apply for and obtain Institutional Review     Board, or IRB, approval of the <font color="blue">proposed investigation</font></td>
    </tr>
    <tr>
      <td>In addition, if the     <font color="blue">clinical study involves</font> a “<font color="blue">significant</font> risk” (as defined by the FDA) to     human health, the sponsor of the <font color="blue">investigation must also submit</font> and obtain     FDA approval of an <font color="blue">investigational</font> device exemption, or IDE, <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>Most of our products to date have been considered <font color="blue">significant</font> risk devices     requiring IDE <font color="blue">approval prior</font> to <font color="blue">investigational</font> use</td>
    </tr>
    <tr>
      <td>We may not be able to     obtain FDA and/or IRB approval to undertake <font color="blue">clinical trials</font> in the US for     any new devices we intend to market in the <font color="blue"><font color="blue">United States</font> </font>in the future</td>
    </tr>
    <tr>
      <td>If     we obtain <font color="blue">such approvals</font>, we may not be able to <font color="blue">comply with</font> the IDE and     other <font color="blue">regulations</font> governing clinical <font color="blue">investigations</font> or the data from any     <font color="blue">such trials may</font> not <font color="blue">support clearance</font> or approval of the <font color="blue">investigational</font>     device</td>
    </tr>
    <tr>
      <td>Failure to obtain <font color="blue">such approvals</font> or to <font color="blue">comply with</font> such <font color="blue">regulations</font>     could have a material adverse effect on our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>COMPLYING WITH FDA REGULATIONS IS AN EXPENSIVE AND TIME-CONSUMING PROCESS,     AND OUR FAILURE TO COMPLY FULLY COULD SUBJECT US TO SIGNIFICANT ENFORCEMENT     ACTIONS          Because  our  products,  including  the  da Vinci Surgical System, are     commercially distributed, numerous postmarket <font color="blue">regulatory</font> <font color="blue">requirement</font>s apply,     including the following:           •   Quality System Regulation, or QSR, which requires <font color="blue">manufacture</font>rs to     follow elaborate design, testing, control, documentation and other quality     <font color="blue">assurance procedures during</font> the <font color="blue"><font color="blue">manufacturing</font> process</font>;           •   labeling <font color="blue">regulations</font>;           •   the FDA’s <font color="blue">general prohibition against false</font> or <font color="blue">misleading statements</font>     in the labeling or promotion of products for unapproved or “off-label” uses;                                           24     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>  •   the Reports of <font color="blue">Corrections and Removals </font>regulation, which requires     that <font color="blue">manufacture</font>rs report to the FDA recalls and <font color="blue">field corrective actions</font>     taken to reduce a risk to health or to remedy a violation of the FFDCA that     may pose a risk to health; and           •   the <font color="blue">Medical Device Reporting </font>regulation, which requires that     <font color="blue">manufacture</font>rs report to the FDA if their device may have caused or     contributed to a death or <font color="blue">serious injury</font> or <font color="blue">malfunctioned</font> in a way that     <font color="blue">would likely</font> cause or contribute to a death or <font color="blue">serious injury</font> if it were to     recur</td>
    </tr>
    <tr>
      <td>We  are subject to inspection and <font color="blue">marketing surveillance by</font> the FDA to     determine our <font color="blue">compliance with</font> <font color="blue">regulatory</font> <font color="blue">requirement</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>finds that     we have failed to comply, it can institute a wide variety of <font color="blue">enforcement</font>     actions, ranging from a <font color="blue">regulatory</font> letter to a <font color="blue">public warning letter</font> to more     <font color="blue">severe civil</font> and <font color="blue">criminal sanctions</font></td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with</font> applicable     <font color="blue">requirement</font>s could lead to an <font color="blue">enforcement</font> action that may have an adverse     effect on our <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have modified the labeling; advertising and <font color="blue">user training</font> for the da     <font color="blue">Vinci Surgical System </font>to call out specific procedures that we believe are     within the scope of our existing 510(k) <font color="blue">clearances</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that the FDA would agree that all such specific procedures are within the     scope of the <font color="blue">existing general clearance</font> or that we have <font color="blue">compiled adequate</font>     information  to  support the safety and efficacy of using the da Vinci     Surgical System for all such specific procedures</td>
    </tr>
    <tr>
      <td>We also have modified the     hardware and software in the da <font color="blue">Vinci Surgical System </font><font color="blue">since clearance</font> in     ways that we believe do not require new 510(k) clearance</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>     you that the FDA <font color="blue">would agree with</font> our de<font color="blue">termination</font>s not to seek new 510(k)     clearance  for any of these changes</td>
    </tr>
    <tr>
      <td><font color="blue">Computer Motion </font><font color="blue">also modified</font> the     hardware and software in its <font color="blue">products subsequent</font> to 510(k) clearance without     <font color="blue">seeking new clearance</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that the FDA <font color="blue">would agree with</font>     the  de<font color="blue">termination</font>s  not to seek new 510(k) clearance for any of these     changes</td>
    </tr>
    <tr>
      <td>The FDA could impose <font color="blue">enforcement</font> sanctions and/or require us to     obtain 510(k) clearance for any <font color="blue">modification</font> to our products or Computer     Motion’s products</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">prohibited from marketing</font> the modified device     until such 510(k) clearance is granted</td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">December </font></font>2002, the FDA inspected our Sunnyvale <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facility</font></font> and     issued a <font color="blue">Form FDA </font>483 setting forth three observed <font color="blue">compliance <font color="blue">deficiencies</font></font>     relating to the QSR and two observed <font color="blue">deficiencies</font> relating <font color="blue">to the Reports </font>of     <font color="blue">Corrections and Removals </font>regulation</td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2003, we wrote to the FDA     indicating  our  response to <font color="blue">each observation with proposed corrective</font>     actions</td>
    </tr>
    <tr>
      <td>That <font color="blue">same month</font>, the FDA <font color="blue">informed us</font> that the adequacy of our     promised  <font color="blue">corrections</font>  and  actions  would be <font color="blue">verified during</font> the next     inspection of our <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We     cannot  assure you that, <font color="blue">upon reinspection</font>, the FDA will find that our     promised  corrective  actions  are  <font color="blue">appropriate</font> or that they have been     <font color="blue">adequately implemented</font></td>
    </tr>
    <tr>
      <td>We also <font color="blue">cannot assure</font> you that the FDA will not find     other <font color="blue">deficiencies</font> in our <font color="blue">compliance with</font> the QSR and other postmarket     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In  June 2003, we acquired <font color="blue">Computer Motion </font>and have integrated its FDA     <font color="blue">compliance quality system into</font> our own</td>
    </tr>
    <tr>
      <td>As a result of the integration and     review, we identified that <font color="blue">Computer Motion </font>has had <font color="blue">deficiencies</font> in complaint     handling, MDR reporting and <font color="blue">Corrections and Removals </font>reporting in the last     <font color="blue">several years</font> that required submission of <font color="blue">retroactive</font> reports to the <font color="blue">FDA We     </font>reported 52 MDRs and we believe that our reporting <font color="blue">decisions</font> regarding these     52 <font color="blue">complaints</font> is <font color="blue">conservative</font> in part because many of the <font color="blue">complaints</font> likely     would not have <font color="blue">been reportable</font> if more information had <font color="blue">been available</font></td>
    </tr>
    <tr>
      <td>Also,     to our knowledge, none of the reported events resulted in a death or serious     injury, prolonged hospitalization, or <font color="blue">medical intervention</font> to <font color="blue">prevent death</font>     or <font color="blue">serious injury</font></td>
    </tr>
    <tr>
      <td><font color="blue">Computer Motion </font>did respond to <font color="blue">complaint trends</font>, and it     addressed the <font color="blue">trends through corrective actions</font></td>
    </tr>
    <tr>
      <td>Accordingly, the incidence     of many of the types of events in the reports had <font color="blue">been mitigated by</font> June     2003</td>
    </tr>
    <tr>
      <td>Our <font color="blue">review also</font> suggests that <font color="blue">significant</font> <font color="blue">complaint trends</font> identified     by  Computer  Motion  over  the period of four years were <font color="blue">addressed by</font>     corrective actions, which have proven to be <font color="blue">effective</font> over time</td>
    </tr>
    <tr>
      <td>Computer     Motion’s product <font color="blue">modification</font>s were completed without 510(k) clearance and     we believe that they do not require new 510(k) clearance</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>     you that the FDA <font color="blue">would agree with</font> our de<font color="blue">termination</font>s not to seek new 510(k)     clearance for any of these changes</td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>We  <font color="blue">cannot assure</font> you that the FDA will not seek to impose <font color="blue">enforcement</font>     <font color="blue">actions on us</font> for <font color="blue">Computer Motion </font><font color="blue">violations preceding</font> our <font color="blue">acquisition</font> of     Computer Motion, that the FDA will agree that since the <font color="blue">acquisition</font> we have     corrected all <font color="blue">regulatory</font> problems, or that our review of Computer Motion’s     <font color="blue">complaint handling will</font> not lead us to <font color="blue">initiate recalls</font> or field actions to     <font color="blue">remedy problems with</font> <font color="blue">Computer Motion </font><font color="blue">products already</font> in the field</td>
    </tr>
    <tr>
      <td>OUR PRODUCTS ARE SUBJECT TO VARIOUS INTERNATIONAL REGULATORY PROCESSES AND     APPROVAL  REQUIREMENTS IF WE DO NOT OBTAIN AND MAINTAIN THE NECESSARY     INTERNATIONAL REGULATORY APPROVALS, WE WILL NOT BE ABLE TO MARKET AND SELL     OUR PRODUCTS IN FOREIGN COUNTRIES          To be able to market and sell our products in other countries, we must     obtain  <font color="blue">regulatory</font>  approvals and <font color="blue">comply with</font> the <font color="blue">regulations</font> of those     countries</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font>, including the <font color="blue">requirement</font>s for approvals and     the time required for <font color="blue">regulatory</font> review, vary from country to country</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font>and maintaining foreign <font color="blue">regulatory</font> approvals are expensive, and we     cannot be certain that we will receive <font color="blue">regulatory</font> approvals in any foreign     country  in which we plan to market our products</td>
    </tr>
    <tr>
      <td>If we fail to obtain     <font color="blue">regulatory</font> approval in any <font color="blue">foreign country</font> in which we plan to market our     products, our ability to <font color="blue">generate revenue will</font> be harmed</td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue">European Union</font> </font>requires that <font color="blue">manufacture</font>rs of <font color="blue">medical products</font> obtain     the right to affix the CE mark to their products before <font color="blue">selling them</font> in     member countries of the <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td>The CE mark is an <font color="blue">international</font>     symbol of adherence to <font color="blue">quality assurance standards</font> and <font color="blue">compliance with</font>     applicable European medical device <font color="blue">directives</font></td>
    </tr>
    <tr>
      <td>In order to obtain the right     to affix the CE mark to products, a <font color="blue">manufacture</font>r must obtain <font color="blue">certification</font>     that its <font color="blue">processes meet certain</font> European <font color="blue">quality standards</font></td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>1999,     we received <font color="blue">permission</font> to affix the CE mark to our da <font color="blue">Vinci Surgical System </font>    and EndoWrist <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>As  we <font color="blue">modify existing products</font> or develop <font color="blue">new products</font> in the future,     including new <font color="blue">instruments</font>, we apply for <font color="blue">permission</font> to affix the CE mark to     <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>In addition, we will be subject to annual <font color="blue">regulatory</font> audits     in order to maintain the CE mark <font color="blue">permission</font>s we have already obtained</td>
    </tr>
    <tr>
      <td>We do     not know whether we will be able to obtain <font color="blue">permission</font> to affix the CE mark     for new or <font color="blue">modified product</font>s or that we <font color="blue">will continue</font> to meet the quality     and <font color="blue">safety standards</font> required to maintain the <font color="blue">permission</font>s we have already     received</td>
    </tr>
    <tr>
      <td>If we are unable to maintain <font color="blue">permission</font> to affix the CE mark to     our products, we <font color="blue">will no longer</font> be able to sell our products in member     countries of the <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td>IF OUR MANUFACTURING FACILITIES DO NOT CONTINUE TO MEET FEDERAL, STATE OR     EUROPEAN MANUFACTURING STANDARDS, WE MAY BE REQUIRED TO TEMPORARILY CEASE     ALL OR PART OF OUR MANUFACTURING OPERATIONS, WHICH WOULD RESULT IN PRODUCT     DELIVERY DELAYS AND LOST REVENUE          Our  <font color="blue">manufacturing</font>  <font color="blue">facilities</font>  are  subject to <font color="blue">periodic inspection by</font>     <font color="blue">regulatory</font> authorities and our <font color="blue">operations</font> <font color="blue">will continue</font> to be <font color="blue">regulated by</font>     the  FDA  for <font color="blue">compliance with</font> <font color="blue">Good Manufacturing Practice </font><font color="blue">requirement</font>s     contained in the FDA’s Quality System Regulations, or QSR We are also     required to <font color="blue">comply with</font> International Organization for Standardization, or     ISO, <font color="blue">quality system standards</font> in order to produce products for sale in     Europe</td>
    </tr>
    <tr>
      <td>If we fail to continue to <font color="blue">comply with</font> <font color="blue">Good Manufacturing Practice </font>    <font color="blue">requirement</font>s or ISO standards, we may be required to cease all or part of     our <font color="blue">operations</font> until we <font color="blue">comply with</font> these <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We are currently in     <font color="blue">compliance with</font> ISO standards</td>
    </tr>
    <tr>
      <td>The FDA inspected our <font color="blue">Mountain View </font>and     Sunnyvale <font color="blue">facilities</font> in March 2000 and <font color="blue">December </font>2002, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>The Good     Manufacturing Practice <font color="blue">issues raised by</font> the FDA during the <font color="blue">inspections</font>     either were <font color="blue">satisfactorily resolved with</font> the FDA, or we believe can be     resolved by us to the FDA’s satisfaction, although we <font color="blue">cannot assure</font> you that     we will be able to do so</td>
    </tr>
    <tr>
      <td>We continue to be subject to FDA <font color="blue">inspections</font> at     any time</td>
    </tr>
    <tr>
      <td><font color="blue">Maintaining </font><font color="blue">such compliance</font> is <font color="blue">difficult</font> and costly</td>
    </tr>
    <tr>
      <td>We cannot be     certain that our <font color="blue">facilities</font> will be found to <font color="blue">comply with</font> Good Manufacturing     Practice <font color="blue">requirement</font>s or ISO standards in future <font color="blue">inspections</font> and <font color="blue">audits by</font>     <font color="blue">regulatory</font> authorities</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>As required, we are <font color="blue">licensed by</font> the <font color="blue">State of California </font>to <font color="blue">manufacture</font>     <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>We are subject to periodic <font color="blue">inspections</font> by the California     Department of Health Services and, if we are unable to maintain this license     following any future <font color="blue">inspections</font>, we will be unable to <font color="blue">manufacture</font> or ship     any products</td>
    </tr>
    <tr>
      <td>RISKS RELATING TO OUR INTELLECTUAL PROPERTY          IF WE ARE UNABLE TO PROTECT THE INTELLECTUAL PROPERTY CONTAINED IN OUR     PRODUCTS FROM USE BY THIRD PARTIES, OUR ABILITY TO COMPETE IN THE MARKET     WILL BE HARMED          Our <font color="blue">commercial success will depend</font> in part on obtaining patent and other     <font color="blue"><font color="blue">intellectual</font> property</font> protection for the <font color="blue"><font color="blue">technologies</font> contained</font> in our     products, and <font color="blue">on successfully defending</font> our patents and other <font color="blue">intellectual</font>     property against third party <font color="blue">challenges</font></td>
    </tr>
    <tr>
      <td>We will incur substantial costs in     obtaining patents and, if necessary, defending our <font color="blue">proprietary rights</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">patent positions</font> of medical device companies, including ours, can be highly     uncertain and <font color="blue">involve complex</font> and <font color="blue">evolving legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>We     do not know whether we will obtain the <font color="blue">patent protection</font> we seek, or that     the  protection  we  do  obtain will be found valid and enforceable if     challenged</td>
    </tr>
    <tr>
      <td>We  also  do  not know whether we will be able to develop     <font color="blue">additional</font>  patentable  <font color="blue">proprietary <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>If we fail to obtain     <font color="blue">adequate protection</font> of our <font color="blue"><font color="blue">intellectual</font> property</font>, or if any protection we     obtain is reduced or eliminated, others could use our <font color="blue"><font color="blue">intellectual</font> property</font>     <font color="blue">without compensating us</font>, resulting in harm to our business</td>
    </tr>
    <tr>
      <td>We may also     determine that it is in our <font color="blue">best interests</font> to <font color="blue">voluntarily</font> challenge a third     party’s products or patents in <font color="blue">litigation</font> or <font color="blue"><font color="blue">administrative</font> proceedings</font>,     including <font color="blue">patent interferences</font> or <font color="blue">reexaminations</font></td>
    </tr>
    <tr>
      <td>Furthermore, the laws of     certain foreign countries do not protect <font color="blue"><font color="blue">intellectual</font> property</font> rights to the     same extent, as do the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition to patents, we <font color="blue">typically rely on</font> a <font color="blue">combination</font> of <font color="blue">trade secret</font>,     copyright and trademark laws, nondisclosure <font color="blue">agreements</font> and other <font color="blue">contractual</font>     provisions and <font color="blue">technical security measures</font> to protect our <font color="blue">intellectual</font>     property  rights</td>
    </tr>
    <tr>
      <td>Nevertheless, these <font color="blue">measures may</font> not be adequate to     safeguard the <font color="blue"><font color="blue">technology</font> underlying</font> our products</td>
    </tr>
    <tr>
      <td>If they do not protect our     rights adequately, <font color="blue">third parties</font> could use our <font color="blue">technology</font>, and our ability     to  compete  in  the  <font color="blue">market would</font> be reduced</td>
    </tr>
    <tr>
      <td>In addition, employees,     <font color="blue">consultants</font> and others who <font color="blue">participate</font> in developing our <font color="blue">products may breach</font>     their <font color="blue"><font color="blue">agreements</font> with us</font> regarding our <font color="blue"><font color="blue">intellectual</font> property</font>, and we may not     have  adequate  remedies  for  the  breach</td>
    </tr>
    <tr>
      <td>We also may not be able to     <font color="blue">effective</font>ly  protect  our <font color="blue"><font color="blue">intellectual</font> property</font> rights in some foreign     countries</td>
    </tr>
    <tr>
      <td>For a variety of reasons, we may decide not to file for patent,     copyright or trademark protection outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We also realize     that our <font color="blue">trade secret</font>s may become known through other means not currently     <font color="blue">foreseen by us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding </font>our efforts to protect our <font color="blue">intellectual</font>     property, our <font color="blue">competitors</font> may independently develop similar or <font color="blue">alternative</font>     <font color="blue">technologies</font> or products that are equal or superior to our <font color="blue">technology</font> and     <font color="blue">products without infringing</font> any of our <font color="blue"><font color="blue">intellectual</font> property</font> rights, or may     <font color="blue">design around</font> our <font color="blue">proprietary <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>OTHERS MAY ASSERT THAT OUR PRODUCTS INFRINGE THEIR INTELLECTUAL PROPERTY     RIGHTS, WHICH MAY CAUSE US TO ENGAGE IN COSTLY DISPUTES AND, IF WE ARE NOT     SUCCESSFUL IN DEFENDING OURSELVES, COULD ALSO CAUSE US TO PAY SUBSTANTIAL     DAMAGES AND PROHIBIT US FROM SELLING OUR PRODUCTS          There may be <font color="blue"><font color="blue">United States</font> </font>and foreign patents issued to <font color="blue">third parties</font> that     relate to computer-assisted surgery, remote surgery, and minimally invasive     surgery</td>
    </tr>
    <tr>
      <td>Some of these patents may be broad enough to cover one or more     aspects of our present <font color="blue">technology</font>, and may cover aspects of our future     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We do not know whether any of these patents, if challenged,     would  be held valid, enforceable and infringed</td>
    </tr>
    <tr>
      <td>From time to time, we     receive, and likely <font color="blue">will continue</font> to receive, <font color="blue">letters from <font color="blue">third parties</font></font>     <font color="blue">inviting us</font> to license their patents</td>
    </tr>
    <tr>
      <td>We may be sued by, or <font color="blue">become involved</font>     in an <font color="blue">administrative</font> proceeding with, one or more of these <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that a court or <font color="blue">administrative</font> body <font color="blue">would agree with</font> any     arguments or defenses we may have concerning <font color="blue">invalidity</font>, <font color="blue">unenforceability</font> or     non<font color="blue">infringement</font> of any third-party patent</td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">issued patents</font>     of which we are aware, other <font color="blue">parties may</font> have filed, and in the future are     likely to file, patent                                           27     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">application</font>s</font> covering surgical products that are similar or identical to     ours</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any patents issuing from <font color="blue"><font color="blue">application</font>s</font> filed     by a <font color="blue">third party will</font> not cover our products or will not have <font color="blue">priority over</font>     our patent <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>The medical device industry has <font color="blue">been characterized by</font> extensive <font color="blue">litigation</font>     and <font color="blue"><font color="blue">administrative</font> proceedings</font> regarding patents and other <font color="blue">intellectual</font>     property  rights,  and  companies have <font color="blue">employed such actions</font> to gain a     <font color="blue">competitive</font>  advantage</td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> assert <font color="blue">infringement</font> or other     <font color="blue">intellectual</font>  property claims <font color="blue">against us</font>, our technical and <font color="blue">management</font>     <font color="blue">personnel will</font> experience a <font color="blue">significant</font> diversion of time and effort and we     will incur large <font color="blue">expenses defending</font> our company</td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> in any     <font color="blue">patent action</font> are successful, our <font color="blue">patent portfolio may</font> be damaged, we may     have to pay substantial damages, including <font color="blue">treble damages</font>, and we may be     required  to  stop  selling our products or obtain a <font color="blue">license which</font>, if     <font color="blue">available at</font> all, may require us to pay substantial royalties</td>
    </tr>
    <tr>
      <td>We cannot be     certain  that  we will have the <font color="blue">financial resources</font> or the <font color="blue">substantive</font>     arguments to defend our patents from <font color="blue">infringement</font> or claims of <font color="blue">invalidity</font> or     <font color="blue">unenforceability</font>,  or to <font color="blue">defend against allegations</font> of <font color="blue">infringement</font> of     third-party  patents</td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">public announcements</font> related to     <font color="blue">litigation</font> or <font color="blue"><font color="blue">administrative</font> proceedings</font> initiated by us, or initiated or     threatened <font color="blue">against us</font>, could cause our stock price to decline</td>
    </tr>
    <tr>
      <td>OUR PRODUCTS RELY ON LICENSES FROM THIRD PARTIES, AND IF WE LOSE ACCESS TO     THESE TECHNOLOGIES, OUR REVENUES COULD DECLINE          We rely on <font color="blue">technology</font> that we <font color="blue">license from others</font>, including <font color="blue">technology</font> that     is integral to our products</td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into license <font color="blue">agreements</font> with</font>     Brookhill-Wilk, LLC , Hansen Medical, Inc, Heartport, Inc, now part of     Johnson &amp; Johnson, IBM Corporation, Medtronic, Inc, MIT, Olympus Optical     Co, Ltd</td>
    </tr>
    <tr>
      <td>and <font color="blue">SRI International</font></td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">agreements</font> may be terminated     for breach</td>
    </tr>
    <tr>
      <td>If any of these <font color="blue">agreements</font> is terminated, we may be unable to     reacquire the <font color="blue">necessary license on</font> satisfactory terms, or at all</td>
    </tr>
    <tr>
      <td>The loss     or  failure  to maintain these <font color="blue">licenses could prevent</font> or <font color="blue">delay further</font>     <font color="blue">development</font> or <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>RISKS RELATING TO OUR TRADING MARKETS          OUR  FUTURE  OPERATING  RESULTS  MAY  BE BELOW SECURITIES ANALYSTS’ OR     INVESTORS’ EXPECTATIONS, WHICH COULD CAUSE OUR STOCK PRICE TO DECLINE          Due to the nascent nature of our industry, we have limited <font color="blue">insight into</font>     trends that may emerge in our market and affect our business</td>
    </tr>
    <tr>
      <td>The revenue     and <font color="blue">income potential</font> of our market are unproven, and we may be unable to     continue to generate <font color="blue">significant</font> revenues</td>
    </tr>
    <tr>
      <td>In addition, our costs may be     <font color="blue">higher than</font> we anticipated</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">generate sufficient revenues</font> or     our costs are <font color="blue">higher than</font> we expect, our results of <font color="blue">operations</font> will suffer</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">future revenue from sales</font> of our products is <font color="blue">difficult</font> to forecast     because the market for new surgical <font color="blue">technologies</font> is <font color="blue">still evolving</font></td>
    </tr>
    <tr>
      <td>Our     results of <font color="blue">operations</font> will depend upon numerous factors, including:           •   the extent to which our products gain market <font color="blue">acceptance</font>;           •   actions relating to <font color="blue">regulatory</font> matters;           •   our timing and ability to develop our <font color="blue">manufacturing</font> and sales and     <font color="blue">marketing capabilities</font>;           •   demand for our products;           •   the size and timing of <font color="blue">particular sales</font> and any <font color="blue">collection delays</font>     related to those sales;           •   <font color="blue">product quality</font> and <font color="blue">supply problems</font>;           •   the progress of <font color="blue">surgical training</font> in the use of our products;           •   our ability to develop, introduce and <font color="blue">market new</font> or <font color="blue">enhanced versions</font>     of our <font color="blue">products on</font> a <font color="blue">timely basis</font>;           •   third-party payor <font color="blue">reimbursement</font> policies;           •   our ability to protect our <font color="blue">proprietary rights</font> and <font color="blue">defend against third</font>     party <font color="blue">challenges</font>;                                           28     ______________________________________________________________________    [54]Table of <font color="blue">Contents       </font>  •   our ability to license <font color="blue">additional</font> <font color="blue"><font color="blue">intellectual</font> property</font> rights; and           •   the progress and results of <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Our  operating results in any <font color="blue">particular period will</font> not be a reliable     <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>It is likely that in some future     quarters, our operating results will be below the <font color="blue">expectations</font> of securities     analysts or investors</td>
    </tr>
    <tr>
      <td>If this occurs, the price of our <font color="blue">common stock</font>, and     the value of your investment, will likely decline</td>
    </tr>
    <tr>
      <td>OUR STOCK PRICE HAS BEEN, AND WILL LIKELY CONTINUE TO BE, VOLATILE          The <font color="blue">market price</font> of our <font color="blue">common stock</font> has experienced <font color="blue">fluctuations</font> and is     likely  to  fluctuate <font color="blue">significant</font>ly in the future</td>
    </tr>
    <tr>
      <td>Our stock price can     fluctuate for a number of reasons, including:           •   <font color="blue">announcements about us</font> or our <font color="blue">competitors</font>;           •   quarterly <font color="blue">variations</font> in operating results;           •   <font color="blue">introduction</font> or <font color="blue">abandonment</font> of new <font color="blue">technologies</font> or products;           •   changes in <font color="blue">product pricing policies</font>;           •   changes in earnings estimates <font color="blue">by analysts</font> or changes in <font color="blue">accounting</font>     policies, including expensing <font color="blue">stock options</font> in <font color="blue">accordance with</font> <font color="blue">Statement </font>of     Financial Accounting Standard (SFAS) Nodtta 123R, “Shared-Based Payment;” and           •   economic changes and political <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>In addition, stock markets have experienced <font color="blue">significant</font> price and volume     <font color="blue">volatility</font> in the past</td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has had a substantial effect on the     <font color="blue">market price</font>s of securities of many <font color="blue">public companies</font> for <font color="blue">reasons frequently</font>     unrelated or <font color="blue">disproportionate</font> to the operating performance of the specific     companies</td>
    </tr>
    <tr>
      <td>In addition, the securities of many medical device companies,     including Intuitive Surgical, have <font color="blue">historically been</font> subject to extensive     price and volume <font color="blue">fluctuations</font> that may affect the <font color="blue">market price</font> of their     common  stock</td>
    </tr>
    <tr>
      <td>If  these broad market <font color="blue">fluctuations</font> continue, they may     <font color="blue">adversely affect</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>